drugset / Trial / NCT02134210

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

NCT02134210

Phase 3 Completed 521 enrolled Coherus Oncology, Inc. Shire · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).

Timeline

Start
2014-06-16
Primary completion
2015-07-27
Completion
2016-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CHS-0214 Unknown 50 mg Subcutaneous
Comparator Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications